October 20, 2015 / 12:09 PM / 2 years ago

BRIEF-GlaxoSmithKline reports positive data for Incruse Ellipta comparisons

Oct 20 (Reuters) - Glaxosmithkline Plc

* Positive data for Incruse Ellipta comparisons

* Positive results from two head-to-head studies directly comparing efficacy and safety of Incruse  Ellipta 

* Results from study 201316 showed that Umeclidinium 62.5mcg achieved a statistically significant improvement in lung function

* Results from randomised, open-label study 201315 showed that Umeclidinium 62.5mcg once daily was non-inferior to Glycopyrronium 44mcg administered once daily

* In study 201316, most commonly reported on-treatment adverse events for both drugs were headache and nasopharyngitis

* In study 201315, most commonly reported on-treatment adverse events for both Umeclidinium and Glycopyrronium were headache Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below